Tuesday, 11 November / 4:45 PM - 5:45 PM  
**W15: MIXED METHODS RESEARCH WITHIN CLINICAL TRIALS: OPERATIONAL CONSIDERATIONS**  
Alexia Marrel, BA, Associate Director, Health Economics and Outcomes Research, Mapi, Lyon, France  
Frederico Calado, PharmD, Associate Director, Global Patient Assess, Novartis, East Hanover, NJ, USA  
Jean-Bernard Gruenberger, MPH, Global HEOR Director, GPA (Global Patient Access), Novartis, Basel, Switzerland  
Xavier Fournie, MD, Executive Vice President, Global Medical Affairs, Global Medical Affairs RWE, Mapi, Lyon, France

**W25: HOW CAN PATIENT ONLINE COMMUNITIES INFORM INDUSTRY ABOUT BARRIERS TO MEDICATION ACCEPTANCE AND UNMET NEEDS? LESSONS LEARNED FROM A FRENCH MULTIDISEASES STUDY USING A PATIENT ONLINE**  
H. Gilet, MSc, Senior Research Manager, HEOR & Strategic Market Access, Mapi, Lyon, France  
Michael Chekroun, MSc, CEO, carenity.com, Paris, France  
Benoit Arnould, PhD, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France

Wednesday, 12 November / 1:45 PM - 2:45 PM  
**W25: HOW CAN PATIENT ONLINE COMMUNITIES INFORM INDUSTRY ABOUT BARRIERS TO MEDICATION ACCEPTANCE AND UNMET NEEDS? LESSONS LEARNED FROM A FRENCH MULTIDISEASES STUDY USING A PATIENT ONLINE**  
H. Gilet, MSc, Senior Research Manager, HEOR & Strategic Market Access, Mapi, Lyon, France  
Michael Chekroun, MSc, CEO, carenity.com, Paris, France  
Benoit Arnould, PhD, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France

Wednesday, 12 November / 3:00 PM - 4:00 PM  
**W33: INTEGRATING THE PATIENT PERSPECTIVE IN THE ASSESSMENT OF BENEFITS AND RISKS OF MEDICINES**  
Benoit Arnould, PhD, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France  
Carla Dias Barbosa, MSc, Senior Research Manager, HEOR & Strategic Market Access, Mapi, Lyon, France  
Kimberley Hockley, MPH, Research Postgraduate and Team Leader for Patients and Public Involvement working group of the IMI-PROTECT Work Package Five, School of Public Health, Imperial College London, London, UK  
Donald L. Patrick, PhD, MSPH, Professor, Department of Health Services and Director, Seattle Quality of Life Group and Biobehavioral Cancer Training Program, University of Washington, Seattle, WA, USA

Wednesday, 12 November / 10:00 AM - 11:00 AM  
**IP20: CAN MIXED METHODS RESEARCH BE THE SOLUTION TO THE CHALLENGES OF PATIENT-CENTERED OUTCOME RESEARCH IN THE CONTEXT OF RARE DISEASES?**  
Moderator: Antoine Regnault, PhD, Research Director, HEOR & Strategic Market Access, Mapi, Lyon, France  
Panelists: Benoit Arnould, PhD, Senior Director, HEOR & Strategic Market Access, Mapi, Lyon, France  
François Houyez, MSc, Treatment Information and Access Director & Health Policy Advisor, European Organisation for Rare Diseases (Eurordis), Paris, France  
Tara Symonds, PhD, Head of PRO Centre of Excellence, Global Market Access, Global Health and Value, Pfizer Ltd., Tadworth, UK

Monday, 10 November  
**SESSION I: 2:15 PM - 3:15 PM**  
**MO3: EXTRAPOLATION OF TRIAL-BASED SURVIVAL CURVES USING EXTERNAL INFORMATION**  
Guyot P1, Welton NJ2, Beasley M2, Ades A2  
1Mapi, The Netherlands; 2University of Bristol, UK; 3Bristol Haematology and Oncology Centre, UK

**SESSION II: 3:30 PM - 4:30 PM**  
**CV1: THE IMPORTANCE OF TREATMENT CLASSIFICATIONS THAT ACCOUNT FOR CONCOMITANT TREATMENTS IN THE CONTEXT OF A NETWORK META-ANALYSIS COMPARING PHARMACOLOGICAL TREATMENTS FOR CHRONIC HEART FAILURE**  
Burnett H1, Cope S1, Vieira MC2, Sagkriotis A1, Senni M4, Deschaseaux C3  
1Mapi, Canada; 2Novartis Pharma, Health Economics and Outcomes Research, USA; 3Novartis Pharma AG, Basel, Switzerland; Scompeno e Trapianti di Cuore, Bergamo, Italy
POSTER SESSION II

Monday, 10 November / 6:30 PM – 7:30 PM

PHP159: AN EXAMINATION OF THE REGULATORY AND REIMBURSEMENT PROCESSES FOR BIOBETTERS AND COMPARISON WITH BIOSIMILARS

de Silva SU, Dimova M, Bending MW – Mapi, UK

PUK27: ACCEPT® QUESTIONNAIRE: RELATION BETWEEN ACCEPTANCE AND COMPLIANCE IN LIVER- AND KIDNEY-TRANSPLANTED PATIENTS CONVERTED TO ONCE-DAILY TACROLIMUS

Bourhis Y1, Chretin S1, Cantarovich D2, Gilet H1, Bugnard F1, Arnould B1 – 1Mapi, France; 2CHU Nantes, France

PMH14: THE PREVALENCE AND DISEASE BURDEN OF TREATMENT-RESISTANT DEPRESSION – A SYSTEMATIC REVIEW OF THE LITERATURE

Kubitsch N1, Vossen C2, Papadimitropoulou K2, Karabis A2 – 1Janssen-Cilag GmbH, Germany; 2Mapi, The Netherlands

POSTER SESSION III

Tuesday, 11 November / 12:30 AM – 1:30 PM

PIH48: PATIENTS’ ACCEPTANCE OF THEIR MEDICATION: RESULTS FROM A FRENCH MULTI-DISEASES STUDY WITH PATIENT ONLINE COMMUNITY USING THE ACCEPTANCE BY THE PATIENTS OF THEIR TREATMENT (ACCEPT®) QUESTIONNAIRE

Gilet H1, Chekrouri M2, Arnould B1 – 1Mapi, France; 2carenity.com, France

PSY85: PSYCHOMETRIC VALIDATION OF THE NEWLY DEVELOPED PHENYLKETONURIA– QUALITY OF LIFE (PKU-QOL) QUESTIONNAIRES ASSESSING THE IMPACT OF PHENYLKETONURIA AND ITS TREATMENT ON PATIENTS’ QUALITY OF LIFE

Bosch AM1, Burlina A2, Cunningham A3, Bettiol EO4, Moreau-Stucker F5, Benmedjahed K4, Regnault A6 – 1University of Amsterdam, The Netherlands; 2University Hospital of Padova, Italy; 3Tuane University School of Medicine, USA; 4University of Geneva Hospitals and Faculty of Medicine, Switzerland; 5EMD Serono Inc, USA; 6Mapi, France

PCV18: CRITICAL APPRAISAL OF NETWORK META-ANALYSES EVALUATING THE EFFICACY AND SAFETY OF NEW ORAL ANTICOAGULANTS IN ATRIAL FIBRILLATION STROKE PREVENTION TRIALS

Cope S1, Clements A2, Hammès F3, Noack H1, Jansen P3 – 1Mapi, The Netherlands; 2Boehringer Ingelheim Pharma GmbH & Co KG, Corporate Deviside Medicine, Germany; 3Boehringer Ingelheim, Paris, France

PSY98: ORPHAN DRUG POLICY: APPROACHES TO MARKET ACCESS IN MULTIPLE COUNTRIES

Shih DY, Jarrett J – Mapi, UK

PIH74: REGULATORY ISSUES IN PRO ADVERTISING: A REVIEW OF THE DDMAC/OPDP LETTERS FROM 1998 TO 2013 TO IDENTIFY PRO CLAIMS VIOLATIONS AND EXAMINE THEIR EVOLUTION OVER TIME

Acquadro C1, Regnault A2, Arnould B2 – 1Mapi Research Trust, France; 2Mapi, France

PSY84: PRO CLAIMS IN ORPHAN MEDICINES APPROVED BY THE EUROPEAN MEDICINES AGENCY (EMA) FOR THE TREATMENT OF LYMPHOPROLIFERATIVE DISORDERS

Acquadro C1, Arnould B2, Perret C1 – 1Mapi Research Trust, France; 2Mapi, France
Tuesday, 11 November / 6:30 PM – 7:30 PM
PRM227 : COST PER PATIENT IN NON INTERVENTIONAL STUDIES AND ADDED VALUE OF DIRECT TO PATIENT CONTACT SERVICE
Fournie X – Mapi, France

PRS79 : SYSTEMATIC LITERATURE REVIEW ASSESSING DATA ON THE BURDEN OF ALLERGIC RHINITIS FROM A COST AND QUALITY OF LIFE PERSPECTIVE
Hahn-Pedersen J1, Boxall N2, Maier W3, Linneberg A4, Serup-Hansen N1 - 1ALK, Denmark; 2Mapi, UK; 3Glostrup University Hospital, Denmark

PRM172: AN ANALYSIS OF THE HEALTH TECHNOLOGY ASSESSMENT RECOMMENDATION AND GUIDANCE ON USE OF EQ-5D-5L IN COST-EFFECTIVENESS MODELING
Ovcinnikova O, Firth ZA, Dimova M - Mapi, UK

PRS6 : SYSTEMATIC REVIEW OF OBSERVATIONAL STUDIES AND RCTS OF OMALIZUMAB IN SEVERE PERSISTENT ALLERGIC ASTHMA AND META-ANALYSIS FEASIBILITY ASSESSMENT
Bergrath E1, Hwa Ong S2, Bousquet J3, Balwin M4, Manga V5, Rao S6, Cope S7 - 1Mapi, USA; 2Novartis Pharma AG, Switzerland; 3University of Montpellier, France; 4Novartis Pharma AG (Employed by Novartis at time of systematic literature review), Switzerland; 5Mapi, Canada

PRM10 : ASSESSING THE RELATIONSHIP BETWEEN TREATMENT EFFECT AND BASELINE RISK IN NETWORK META-ANALYSIS OF MODERATE TO SEVERE CHRONIC PLAQUE PSORIASIS TRIALS
Smiechowski B, Cope S – Mapi, The Netherlands

PRS5: COMPARATIVE EFFICACY OF UMECLIDINIUM BROMIDE VERSUS OTHER LONG-ACTING ANTICHOLINERGIC MONOTHERAPIES AS TREATMENTS FOR COPD PATIENTS
Ismaila AS1, Huisman E2, Punekar YS3 - 1Value Evidence and Outcomes, GlaxoSmithKline, USA; 2Mapi, The Netherlands; 3Value Evidence and Outcomes, GlaxoSmithKline R&D, UK

Perrier LL, Conway K, Acquadro C - Mapi Research Trust

Tuesday, 11 November / 6:30 PM – 7:30 PM
PRM59: eCOA LICENSING: LESSONS LEARNED FROM THE COPYRIGHT OF COA TRANSLATIONS AND SPECIFICITIES OF eCOAs
Anfray C1, Conway K2, Acquadro C3 - 1Mapi, France; 2Mapi Research Trust, France

PRM158: ARE “LIVELY” AND “FULL OF PEP” SIMILAR OR DIFFERENT CONCEPTS? CHALLENGES IN TRANSLATING THESE TERMS IN SEVEN LANGUAGES
Gil-Campos I1, Anfray C1, Acquadro C3 - 1Mapi, France; 2Mapi Research Trust, France

PRM180: DEVELOPMENT OF THE BEHAVIOR RATING INVENTORY OF EXECUTIVE FUNCTION - PRESCHOOL VERSION (BRIEF-P) IN 10 LANGUAGES
Vasarri S1, Isquith PK2, Acquadro C3 - 1Mapi, France; 2Geisel School of Medicine at Dartmouth, USA; 3Mapi Research Trust, France

PRM181: CHALLENGES IN RECRUITING PATIENTS FOR THE LINGUISTIC VALIDATION OF PRO INSTRUMENTS DEVELOPED FOR RARE DISEASES: A CASE STUDY WITH ALAGILLE SYNDROME
Kennedy C1, Abetz-Webb L2, Lambe J3 - 1Lumena Pharmaceuticals, USA; 2Patient-Centred Outcomes Ltd, UK; 3Mapi, France
POSTER SESSION V

**Wednesday, 12 November / 12:45 AM – 1:45 PM**

**PIN2: RELATIONSHIP BETWEEN MICROBIOLOGICAL ERADICATION AND CLINICAL OUTCOME WITH ANTIBIOTIC TREATMENT IN NOSOCOMIAL PNEUMONIA, COMPLICATED URINARY TRACT INFECTION, AND COMPLICATED INTRA-ABDOMINAL INFECTION**

Jansen JP<sup>1</sup>, Kauf T<sup>2</sup>, Eapen S<sup>3</sup>, Medic G<sup>4</sup>, Kollef M<sup>5</sup> - Redwood Outcomes, USA; Cubist Pharmaceuticals, USA; Redwood Outcomes, Canada; Mapi, The Netherlands; Barnes Jewish Hospital, USA

**PCN138: COST EFFECTIVENESS OF CETUXIMAB IN 1ST-LINE TREATMENT OF RAS WILD-TYPE METASTATIC COLORECTAL CANCER IN SCOTLAND: A SUMMARY OF THE SUBMISSION TO THE SCOTTISH MEDICINES CONSORTIUM**

Jarrett J<sup>1</sup>, Ovchinnikova O<sup>1</sup>, Hnoosh A<sup>2</sup>, Harty G<sup>3</sup>, Byrne B<sup>2</sup>, von Hohnhorst P<sup>4</sup> - Mapi, UK; Merck Serono Ltd., Feltham, UK; Merck Serono, Darmstadt, Germany

**PCN16: A SYSTEMATIC LITERATURE REVIEW TO IDENTIFY TRIALS IN FIRST-LINE RAS WILD-TYPE (WT) METASTATIC COLORECTAL CANCER (MCRC) PATIENTS**

Jarrett J<sup>1</sup>, Weijers L<sup>2</sup>, Hnoosh A<sup>3</sup>, Harty G<sup>3</sup>, von Hohnhorst P<sup>4</sup> - Mapi, UK; Mapi, The Netherlands; Merck Serono Ltd., Feltham, UK; Merck Serono, Darmstadt, Germany